Temperature-controlled supply chain solutions firm Cryoport has announced the opening of a new 13,400 sq ft IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium.
Already operational, the site will develop, optimise, and validate cryogenic preservation methods for leukapheresis materials used in cell-based therapies.
The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually.
News of the new facility comes just over a month after the company announced a similar site in Houston in support of its InteriCell bioprocessing, cryopreservation, and distribution solution for the cell therapy market.
